Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ALAS2
REST API REST API
Homo sapiens
ALAS2 is differentially expressed in 158 experiments: 37 organism parts: bone marrow, liver, ... (35 more);, 109 disease states: normal, lung adenocarcinoma, ... (107 more);, 54 cell types 67 cell lines 13 compound treatments and 58 other conditions.
Synonyms ASB
Orthologs HEM1 (Saccharomyces cerevisiae)   alas2 (Danio rerio)   Alas2 (Mus musculus)   HEM0_BOVIN (Bos taurus)   Alas (Drosophila melanogaster)   alas2 (Xenopus laevis)   Q28255_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term tetrapyrrole biosynthetic process, protein binding, cellular amino acid metabolic process, mitochondrial inner membrane, transferase activity, transferring nitrogenous groups, pyridoxal phosphate binding, metabolic process, mitochondrial matrix, response to hypoxia, 5-aminolevulinate synthase activity, coenzyme binding, biosynthetic process, heme biosynthetic process, cellular iron ion homeostasis, mitochondrion, transferase activity, transferring acyl groups, erythrocyte differentiation, hemoglobin biosynthetic process, oxygen homeostasis, glycine binding, porphyrin-containing compound metabolic process
InterPro Term 4pyrrol_synth_NH2levulA_synth, Aminotrans_V/Cys_dSase, Aminotransferase_I/II, Cys/Met-Metab_PyrdxlP-dep_enz, 5aminolev_synth_preseq
UniProt Accession Q5JZF5, Q9H366, B7ZB88, P22557, Q6QNT2, A8K6C4, A8K3F0
Gene-Disease Assocation ANEMIA, SIDEROBLASTIC, X-LINKED; XLSA, PROTOPORPHYRIA, ERYTHROPOIETIC, X-LINKED; XLEPP
Search EB-eye ENSG00000158578
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-1577, E-MTAB-24, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-24147, E-GEOD-2450, E-GEOD-19480, E-GEOD-2487, E-MTAB-62, ... (13 experiments)

Factor Value U/D Experiments
primary culture
2
E-GEOD-2450, E-GEOD-1657
ITM-E6E7-ST
1
E-GEOD-2487
UACC893
1
E-MTAB-37
Calu6
1
E-MTAB-37
GDM1
1
E-MTAB-37
SCaBER
1
E-MTAB-37
61 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, E-GEOD-11755, E-MEXP-466, ... (27 experiments)

Factor Value U/D Experiments
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
cardiac myocyte
1
E-MTAB-25
centroblast
1
E-GEOD-15271
hematopoietic stem cell
1
E-MEXP-1403
stromal cell
1
E-GEOD-10797
osteoblast
1
E-MEXP-1216
48 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-2069, E-GEOD-1577, E-GEOD-12254, ... (39 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
prostate carcinoma
3
E-MTAB-62, E-GEOD-96, E-MEXP-2034
chronic myelogenous leukemia
3
E-MTAB-37, E-GEOD-96, E-MTAB-62
dermatomyositis
2
E-GEOD-5370, E-MTAB-62
acute promyelocytic leukemia
1
2
E-GEOD-995, E-GEOD-1729, E-MTAB-62
lung cancer, cytotoxicity
1
E-MTAB-62
103 more value(s).


Compound treatment

studied in E-GEOD-1615, E-MEXP-1269, E-GEOD-412, E-GEOD-2803, E-GEOD-5824, ... (10 experiments)

Factor Value U/D Experiments
none
5
E-GEOD-412, E-GEOD-995, E-GEOD-1615, E-GEOD-5824, E-GEOD-2803 ... (5 experiments)
ethanol
3
1
E-GEOD-3113
ponasterone A
1
E-GEOD-3113
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
glutamine
1
1
E-MEXP-1335
no estradiol
1
E-GEOD-20081
7 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-2191, E-GEOD-4619, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-MTAB-25, E-GEOD-6236, E-TABM-145, E-GEOD-7307, ... (7 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-1561

Environmental stress
studied in E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-17476, E-TABM-601, E-GEOD-1153, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20540, E-MEXP-1446, E-MEXP-2146

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-974, E-MEXP-2069, E-GEOD-1926, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-2634, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1657

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-1343

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.316 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM